Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

61.84USD
28 Feb 2017
Change (% chg)

-- (--)
Prev Close
$61.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,361,453
52-wk High
$68.12
52-wk Low
$54.25

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $98,568.03
Shares Outstanding(Mil.): 1,593.92
Dividend: 0.64
Yield (%): 4.14

Financials

  ABBV.N Industry Sector
P/E (TTM): 16.94 29.14 29.88
EPS (TTM): 3.65 -- --
ROI: 12.09 13.58 13.08
ROE: 138.75 14.48 14.24

BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B

* Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

27 Feb 2017

BRIEF-Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax

* Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

27 Feb 2017

Fitch Affirms Astrazeneca at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, February 22 (Fitch) Fitch Rating has affirmed UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating at 'A'. The Outlook is Stable. The rating remains underpinned by AZ's leading position in the global pharmaceutical sector, supported by a business risk profile characterised by scale, diversification, and focus on innovation. The group is accelerating the dev

22 Feb 2017

BRIEF-Abbvie announces $5 bln increase to stock repurchase program

* Abbvie announces $5 billion increase to stock repurchase program Source text for Eikon: Further company coverage:

17 Feb 2017

BRIEF-Abbvie sets quarterly cash dividend of $0.64 per share

* Sets quarterly cash dividend of $0.64 per share Source text for Eikon: Further company coverage:

16 Feb 2017

BRIEF-Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir

* Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of chronic hepatitis c in all major genotypes (GT1-6) Source text for Eikon: Further company coverage:

01 Feb 2017

BRIEF-AbbVie says continues to see good Humira growth in international markets despite indirect biosimilar competition - Conf Call

* AbbVie says continues to see good Humira growth in international markets despite indirect biosimilar competition: Conf Call

27 Jan 2017

AbbVie revenue rises 6.2 pct

Jan 27 AbbVie Inc reported a 6.2 percent rise in quarterly net revenue, helped by demand for its flagship $15 billion-a-year arthritis treatment, Humira.

27 Jan 2017

BRIEF-Abbvie Inc reports Q4 GAAP earnings per share $0.85

* Abbvie reports full-year and fourth-quarter 2016 financial results

27 Jan 2017

BRIEF-Abbvie initiates phase 2 clinical trial programs for ABBV-8e12

* Abbvie initiates phase 2 clinical trial programs for ABBV-8e12, an investigational anti-tau antibody, in early alzheimer's disease and progressive supranuclear palsy Source text for Eikon: Further company coverage:

25 Jan 2017

More From Around the Web

Competitors

Earnings vs. Estimates